AFT Pharmaceuticals 미래 성장

Future 기준 확인 3/6

AFT Pharmaceuticals (는) 각각 연간 23.7% 및 14.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 25.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.3% 로 예상됩니다.

주요 정보

23.7%

수익 성장률

25.1%

EPS 성장률

Pharmaceuticals 수익 성장	37.2%
매출 성장률	14.1%
향후 자기자본 수익률	17.3%
애널리스트 커버리지	Low
마지막 업데이트	12 Dec 2024

최근 미래 성장 업데이트

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

Recent updates

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 17

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

수익 및 매출 성장 예측

NZSE:AFT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (NZD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	290	23	N/A	14	2
3/31/2026	256	18	N/A	12	3
3/31/2025	215	12	N/A	11	3
9/30/2024	199	12	17	26	N/A
6/30/2024	197	14	18	27	N/A
3/31/2024	195	16	19	29	N/A
12/31/2023	185	13	12	21	N/A
9/30/2023	175	11	4	13	N/A
6/30/2023	166	11	3	12	N/A
3/31/2023	157	11	2	12	N/A
12/31/2022	149	14	4	12	N/A
9/30/2022	141	17	6	13	N/A
6/30/2022	135	18	7	14	N/A
3/31/2022	130	20	9	14	N/A
12/31/2021	125	15	7	12	N/A
9/30/2021	120	11	5	10	N/A
6/30/2021	116	9	0	6	N/A
3/31/2021	113	8	-5	1	N/A
12/31/2020	110	5	-4	3	N/A
9/30/2020	107	3	-2	6	N/A
6/30/2020	107	7	3	10	N/A
3/31/2020	106	12	8	15	N/A
12/31/2019	100	11	7	12	N/A
9/30/2019	94	11	5	9	N/A
6/30/2019	89	4	1	5	N/A
3/31/2019	85	-3	-2	1	N/A
12/31/2018	84	-7	-5	-1	N/A
9/30/2018	83	-11	-8	-4	N/A
6/30/2018	82	-12	N/A	-6	N/A
3/31/2018	81	-14	N/A	-9	N/A
12/31/2017	79	-14	N/A	-13	N/A
9/30/2017	76	-14	N/A	-16	N/A
6/30/2017	73	-16	N/A	-18	N/A
3/31/2017	69	-18	N/A	-19	N/A
12/31/2016	67	-18	N/A	-20	N/A
9/30/2016	64	-18	N/A	-21	N/A
6/30/2016	64	-16	N/A	-17	N/A
3/31/2016	64	-13	N/A	-14	N/A
12/31/2015	63	-13	N/A	-12	N/A
9/30/2015	62	-13	N/A	-10	N/A
6/30/2015	59	-13	N/A	-11	N/A
3/31/2015	56	-13	N/A	-13	N/A
3/31/2014	49	-1	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AFT 의 연간 예상 수익 증가율( 23.7% )이 saving rate( 3% 보다 높습니다. ).

수익 vs 시장: AFT 의 연간 수익( 23.7% ) NZ 시장( 24.2% 보다 느리게 성장할 것으로 예상됩니다. 24.2% 연간).

고성장 수익: AFT 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: AFT 의 수익(연간 14.1% ) NZ 시장( 4.4% 보다 빠르게 성장할 것으로 예상됩니다. 4.4% 연간).

고성장 수익: AFT 의 수익(연간 14.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AFT 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 17.3 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/28 23:55
장 마감 주가	2024/12/27 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

AFT Pharmaceuticals Limited 7 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
John Hester	Bell Potter
Jack Crowley	Credit Suisse
Soo Romanoff	Edison Investment Research

AFT Pharmaceuticals 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 20%, revenue upgraded

Price target increased by 24% to NZ$4.60

Price target increased by 24% to NZ$4.60

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Recent updates

Consensus EPS estimates fall by 20%, revenue upgraded

First half 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.02 profit in 1H 2024)

AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Investor sentiment deteriorates as stock falls 17%

Price target increased by 24% to NZ$4.60

AFT Pharmaceuticals Limited to Report First Half, 2025 Results on Nov 21, 2024

Price target increased by 24% to NZ$4.60

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Upcoming dividend of NZ$0.016 per share

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Dividend of NZ$0.016 announced

Full year 2024 earnings released: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?